Table 1.
Minimum inhibitory concentration of curcumin, demethoxycurcumin, and their respective synthetic analogues against various mycobacterial strains (μg/mL).
| Compound | Mycobacterial Strains | MIC (μg/mL) | Reference |
|---|---|---|---|
| Curcumin | MTB H37Rv | 16 | [45] |
| Demethoxycurcumin (DM) | MTB H37Rv | 200 | [46] |
| DM6 | MTB H37Rv | 7.8 | |
| DM7 | MTB H37Rv | 125 | |
| Mono-O-methylcurcumin- isoxazole | MTB H37Ra | 0.09 | [47] |
| a INH, RIF, STM-resistant MTB (clinical isolate M3) | 0.195 | ||
| b INH, RIF, EMB, STM-resistant MTB (clinical isolate M4) | 1.56 | ||
| INH, RIF, STM-resistant MTB (clinical isolate M5) | 3.125 | ||
| INH, RIF-resistant MTB (clinical isolate M6) | 0.39 | ||
| INH, RIF, EMB, STM-resistant MTB (clinical isolate M8) | 3.125 | ||
| INH, RIF-resistant MTB (clinical isolate M11) | 3.125 | ||
| INH, RIF, EMB-resistant MTB (clinical isolate M16) | 1.56 | ||
| INH, RIF, EMB, STM-resistant MTB (clinical isolate M21) | 3.125 | ||
| INH, RIF-resistant MTB (clinical isolate M22) | 0.39 | ||
| INH, RIF-resistant MTB (clinical isolate M27) | 0.195 | ||
| c INH, RIF, STM, OFX, CIP-resistant MTB (clinical isolate M46) | 1.56 | ||
| INH, RIF, STM, OFX, CIP-resistant MTB (clinical isolate M48) | 1.56 | ||
| INH, RIF, STM, OFX, CIP-resistant MTB (clinical isolate M53) | 3.125 | ||
| UBS-109 | M. marinum | 10 mM * | [48] |
| MTB H37Rv | ~10 μM * | ||
| EF-24 | MTB Beijing F2 | 20 μM * | |
| M. marinum | 25 mM * | ||
| CPMD-6- dihydrochloride | MTB H37R | 2 | [45] |
| INH-resistant MTB ATCC 35822 | 2 | ||
| RIF-resistant MTB ATCC 35838 | 2 | ||
| STM-resistant MTB ATCC 35820 | 2 | ||
| ETB-resistant MTB ATCC 35837 | 2 | ||
| M. fortuitum ATCC 6841 | 16 | ||
| M.abscessus ATCC 19977 | 16 | ||
| 3,3′-Dihydroxycurcumin | MTB | 156 | [49] |
| Quinolidene based monocarbonyl curcumin analogue 3e | MTB | >30 # | [50] |
| M. bovis BCG | 2.7 # | ||
| Quinolidene based monocarbonyl curcumin analogue 3h | MTB | >30 # | |
| M. bovis BCG | 9.2 # | ||
| Quinolidene based monocarbonyl curcumin analogue 4a | MTB | 26.5 # | |
| M. bovis BCG | 7.3 # | ||
| Quinolidene based monocarbonyl curcumin analogue 4e | MTB | 7.8 # | |
| M. bovis BCG | 9.4 # |
* IC50 of UBS-109 EF-24 against the mycobacterial strains; a INH, isoniazid; RIF, rifampicinn; STM, streptomycin; b EMB, ethambutol; c OFX, ofloxacin; CIP, ciprofloxacin; # MIC90.